IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 7.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 104,900 shares of the company's stock after selling 8,616 shares during the period. Stephens Investment Management Group LLC owned about 0.13% of IDEXX Laboratories worth $52,998,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Crewe Advisors LLC bought a new position in shares of IDEXX Laboratories during the 1st quarter worth approximately $26,000. Ridgewood Investments LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $27,000. Institutional & Family Asset Management LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $28,000. E Fund Management Hong Kong Co. Ltd. raised its stake in shares of IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock worth $29,000 after acquiring an additional 57 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock worth $34,000 after acquiring an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

IDXX traded up $10.36 during midday trading on Friday, hitting $417.28. 994,132 shares of the company traded hands, compared to its average volume of 490,774. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $34.35 billion, a price-to-earnings ratio of 41.69, a PEG ratio of 3.94 and a beta of 1.33. IDEXX Laboratories, Inc. has a 52-week low of $395.37 and a 52-week high of $583.39. The business has a 50 day simple moving average of $480.17 and a two-hundred day simple moving average of $487.66.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.69 by $0.11. The business had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The company's revenue was up 6.6% compared to the same quarter last year. During the same period last year, the firm posted $2.53 earnings per share. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research note on Thursday, October 10th. StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, July 10th. JPMorgan Chase & Co. cut their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. BTIG Research assumed coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They set a "buy" rating and a $580.00 price target on the stock. Finally, Piper Sandler cut their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $574.13.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.